文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

宫颈癌外照射放疗新方法:虚拟直或弯曲推量区的可行性研究

A novel external beam radiotherapy method for cervical cancer patients using virtual straight or bending boost areas; an in-silico feasibility study.
PubMed 文献 · Radiat Oncol · 2021-06-14

本研究对10例局部晚期宫颈癌患者进行回顾性剂量学研究,探索一种新型空间分割放疗方法,利用虚拟杆状结构在靶区创建不均匀剂量分布。结果显示该技术可获得高质量计划,满足危及器官约束,剂量不均匀性接近常规近距离治疗水平,提示可能开展I期临床试验。

要点

  • 10例局部晚期宫颈癌患者回顾性剂量学研究,处方30 Gy/5次,靶区90%覆盖。
  • SFRT_1和SFRT_2两种策略均满足危及器官约束,膀胱D2cm3分别为22.4±2.0 Gy和13.9±2.9 Gy。
  • 靶区热点V45Gy为43.1±7.5%(SFRT_1)和56.6±5.6%(SFRT_2),剂量不均匀性接近近距离治疗。

核心结论

  • 该新型宫颈推量计划技术可获得高质量计划,满足危及器官约束,剂量不均匀性接近常规近距离治疗水平。

研究设计与样本

  • 回顾性剂量学研究,纳入10例局部晚期宫颈癌患者,基于外照射放疗CT扫描。
  • 处方剂量30 Gy分5次,靶区90%体积覆盖,采用SFRT_1(峰谷策略)和SFRT_2(仅峰策略)生成不均匀剂量分布。
  • 计划目标:CTV D90%≥30 Gy,V45Gy≥50-55%,V60Gy≥30%;危及器官D2cm3约束:膀胱≤23.75 Gy、直肠≤17.0 Gy、乙状结肠≤19.5 Gy、肠道≤17.0 Gy。

主要发现

  • 膀胱D2cm3为22.4±2.0 Gy(SFRT_1)和13.9±2.9 Gy(SFRT_2),直肠为13.9±2.9 Gy(SFRT_1)和13.2±3.0 Gy(SFRT_2)。
  • 乙状结肠D2cm3为2.6±3.1 Gy(SFRT_1)和2.8±3.0 Gy(SFRT_2),肠道为9.1±5.9 Gy(SFRT_1)和9.7±7.3 Gy(SFRT_2)。
  • 靶区热点V45Gy为43.1±7.5%(SFRT_1)和56.6±5.6%(SFRT_2),V60Gy为15.4±5.6%(SFRT_1)和26.8±6.6%(SFRT_2)。
  • 考虑定位不确定性,处方可提升至CTV D90%=33-35 Gy而不违反危及器官约束。

关键数值与推荐

  • 靶区计划目标:D90%≥30 Gy,V45Gy≥50-55%,V60Gy≥30%。
  • 危及器官D2cm3约束:膀胱≤23.75 Gy,直肠≤17.0 Gy,乙状结肠≤19.5 Gy,肠道≤17.0 Gy。
  • 剂量提升潜力:CTV D90%可至33-35 Gy而不 compromise 危及器官约束。

临床怎么用

  • 该技术可能作为宫颈癌推量放疗的替代方法,尤其适用于无法接受近距离治疗的患者。
  • 计划设计时需根据患者解剖个性化虚拟杆的位置、直径、间距和排列。
  • 需注意定位不确定性,可考虑将处方剂量提升至D90%=33-35 Gy。

局限性

  • 基于10例患者的回顾性剂量学研究,样本量小。
  • 仅为计划可行性研究,未报告临床结局或毒性数据。
  • 需进一步开展I期临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To investigate the potential role of a novel spatially fractionated radiation therapy (SFRT) method where heterogeneous dose patterns are created in target areas with virtual rods, straight or curving, of variable position, diameter, separation and alignment personalised to a patient's anatomy. The images chosen for this study were CT scans acquired for the external beam part of radiotherapy. METHODS: Ten patients with locally advanced cervical cancer were retrospectively investigated with SFRT. The dose prescription was 30 Gy in 5 fractions to 90% target volume coverage. Peak-and-valley (SFRT_1) and peak-only (SFRT_2) strategies were applied to generate the heterogeneous dose distributions. The planning objectives for the target (CTV) were D90% ≥ 30 Gy, V45Gy ≥ 50-55% and V60Gy ≥ 30%. The planning objectives for the organs at risk (OAR) were: D2cm3 ≤ 23.75 Gy, 17.0 Gy, 19.5 Gy, 17.0 Gy for the bladder, rectum, sigmoid and bowel, respectively. The plan comparison was performed employing the quantitative analysis of the dose-volume histograms. RESULTS: The D2cm3 was 22.4 ± 2.0 (22.6 ± 2.1) and 13.9 ± 2.9 (13.2 ± 3.0) for the bladder and the rectum for SFRT_1 (SFRT_2). The results for the sigmoid and the bowel were 2.6 ± 3.1 (2.8 ± 3.0) and 9.1 ± 5.9 (9.7 ± 7.3), respectively. The hotspots in the target volume were V45Gy = 43.1 ± 7.5% (56.6 ± 5.6%) and V60Gy = 15.4 ± 5.6% (26.8 ± 6.6%) for SFRT_1 (SFRT_2). To account for potential uncertainties in the positioning, the dose prescription could be escalated to D90% = 33-35 Gy to the CTV without compromising any constraints to the OARs CONCLUSION: In this dosimetric study, the proposed novel planning technique for boosting the cervix uteri was associated with high-quality plans, respecting constraints for the organs at risk and approaching the level of dose heterogeneity achieved with routine brachytherapy. Based on a sample of 10 patients, the results are promising and might lead to a phase I clinical trial.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Cozzi L, Beriwal S, Kuusela E, et al. A novel external beam radiotherapy method for cervical cancer patients using virtual straight or bending boost areas; an in-silico feasibility study. Radiat Oncol. 2021. PMID: 34127013. doi:10.1186/s13014-021-01838-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。